Cancer Survivorship Training Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

BETHESDA, Md-In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues cancer survivors face.

BETHESDA, Md—In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues cancer survivors face.

The training program was developed by NCI’s Office of Cancer Information, Communication, and Education in collaboration with Ortho Biotech Inc., the National Coalition for Cancer Survivorship, and cancer organizations nationwide.

To obtain a free copy of the training program, please contact the NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

Articles in this issue
Tobacco Companies Reach Settlement With Texas for $15.3 Billion
Archives to Collect Info on Radiation Exposure Worldwide
Few BRCA-1 Carriers Take Recommended Precautions
Lifelong Weight Control a Key to Breast Ca Prevention
Eight-Year Prostate Brachytherapy Update Shows Good Results
Patient Brochure on Breast Cancer Tumor Markers
Gay Men’s Health Crisis Calls for HIV Reporting in New York
Single-Agent Taxanes in Advanced Breast Cancer: A Commentary
ODAC Declines to Vote on DepoCyt FDA Recommendation
Photofrin Approved for Early-Stage Lung Cancer
Breast Cancer Diagnosed After Childbirth May Be More Severe
NCCN Forum: Who Pays for Clinical Trials?
AHCPR Smoking Interventions Are Cost Effective
Senator Urges Consensus on Tobacco Law
Thomas Jefferson Opens New Familial Colorectal Cancer Registry
Recent Videos
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Related Content
Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.

Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC

Roman Fabbricatore
October 11th 2024
Article

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Regardless of type 2 diabetes status, pancreatic cancer risk was reduced with metabolic-bariatric surgery for patients who were obese.

Metabolic-Bariatric Surgery Reduces Pancreatic Cancer Risk in Obese Group

Ariana Pelosci
October 11th 2024
Article

Regardless of type 2 diabetes status, pancreatic cancer risk was reduced with metabolic-bariatric surgery for patients who were obese.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer

Russ Conroy
October 10th 2024
Article

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.

Talazoparib/Enzalutamide Combo Prolongs Survival in Metastatic CRPC

Russ Conroy
October 10th 2024
Article

Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.